[{"orgOrder":0,"company":"Lundquist Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lundquist Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Drugs For Neglected Diseases Initiative","sponsor":"Inserm-ANRS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Drugs For Neglected Diseases Initiative","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drugs For Neglected Diseases Initiative \/ Inserm-ANRS","highestDevelopmentStatusID":"10","companyTruncated":"Drugs For Neglected Diseases Initiative \/ Inserm-ANRS"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"||NAD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"||NAD","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Sara\u2019s Cure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ World Health Organization"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"VLP Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm holding \/ VLP Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm holding \/ VLP Therapeutics"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||Sphingosine kinase 2","graph1":"Oncology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CARE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARE \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Cardresearch","sponsor":"Cardresearch | Cytel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cardresearch","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardresearch \/ Cardresearch | Cytel","highestDevelopmentStatusID":"10","companyTruncated":"Cardresearch \/ Cardresearch | Cytel"},{"orgOrder":0,"company":"Pulmoquine Therapeutics, Inc","sponsor":"Rockefeller University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pulmoquine Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pulmoquine Therapeutics, Inc \/ Rockefeller University","highestDevelopmentStatusID":"6","companyTruncated":"Pulmoquine Therapeutics, Inc \/ Rockefeller University"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"German Center for Diabetes Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apsen Farmaceutica \/ German Center for Diabetes Research","highestDevelopmentStatusID":"10","companyTruncated":"Apsen Farmaceutica \/ German Center for Diabetes Research"},{"orgOrder":0,"company":"Kimberly Perez","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Kimberly Perez","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kimberly Perez \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Kimberly Perez \/ Eli Lilly"},{"orgOrder":0,"company":"Abderrahmane Mami Hospital","sponsor":"Gangnam Severance Hospital | Datametrix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TUNISIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Abderrahmane Mami Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix","highestDevelopmentStatusID":"10","companyTruncated":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix"},{"orgOrder":0,"company":"Abderrahmane Mami Hospital","sponsor":"Gangnam Severance Hospital | Datametrix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TUNISIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Abderrahmane Mami Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix","highestDevelopmentStatusID":"10","companyTruncated":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Institut Pasteur","highestDevelopmentStatusID":"10","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Institut Pasteur"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","highestDevelopmentStatusID":"10","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang"},{"orgOrder":0,"company":"Fundaci\u00f3n FLS","sponsor":"Germans Trias i Pujol Hospital | Department of Health, Catalonia | Gebro Pharma | Rubio Laboratories | Institut Catal\u00e0 de Salut","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fundaci\u00f3n FLS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fundaci\u00f3n FLS \/ Germans Trias i Pujol Hospital | Department of Health, Catalonia | Gebro Pharma | Rubio Laboratories | Institut Catal\u00e0 de Salut","highestDevelopmentStatusID":"10","companyTruncated":"Fundaci\u00f3n FLS \/ Germans Trias i Pujol Hospital | Department of Health, Catalonia | Gebro Pharma | Rubio Laboratories | Institut Catal\u00e0 de Salut"},{"orgOrder":0,"company":"ScandiBio Therapeutics","sponsor":"Istanbul Medipol University Hospital | Istanbul Umraniye Training and Research Hospital | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Bagcilar Training and Research Hospital | Kanuni Su","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ScandiBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ScandiBio Therapeutics \/ Istanbul Medipol University Hospital | Istanbul Umraniye Training and Research Hospital | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Bagcilar Training and Research Hospital | Kanuni Su","highestDevelopmentStatusID":"9","companyTruncated":"ScandiBio Therapeutics \/ Istanbul Medipol University Hospital | Istanbul Umraniye Training and Research Hospital | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Bagcilar Training and Research Hospital | Kanuni Su"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Rabin Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Rabin Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Rambam Health Care Campus \/ Rabin Medical Center"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Perseverance Research Center, LLC","sponsor":"Athena Medical Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Perseverance Research Center, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perseverance Research Center, LLC \/ Athena Medical Group","highestDevelopmentStatusID":"7","companyTruncated":"Perseverance Research Center, LLC \/ Athena Medical Group"},{"orgOrder":0,"company":"Kootenai Health","sponsor":"Washington State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kootenai Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kootenai Health \/ Washington State University","highestDevelopmentStatusID":"11","companyTruncated":"Kootenai Health \/ Washington State University"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"University of Manitoba | University of Alberta | University of British Columbia | McMaster University | London Health Sciences Centre Research Institute (Lawson) | Eastern Health | University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McGill University Health Centre Research Institute \/ University of Manitoba | University of Alberta | University of British Columbia | McMaster University | London Health Sciences Centre Research Institute (Lawson) | Eastern Health | University of Minnesota","highestDevelopmentStatusID":"10","companyTruncated":"McGill University Health Centre Research Institute \/ University of Manitoba | University of Alberta | University of British Columbia | McMaster University | London Health Sciences Centre Research Institute (Lawson) | Eastern Health | University of Minnesota"},{"orgOrder":0,"company":"LSU Health Sciences Center New Orleans","sponsor":"Lafayette General Health | University of Louisiana at Lafayette","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LSU Health Sciences Center New Orleans","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LSU Health Sciences Center New Orleans \/ Lafayette General Health | University of Louisiana at Lafayette","highestDevelopmentStatusID":"10","companyTruncated":"LSU Health Sciences Center New Orleans \/ Lafayette General Health | University of Louisiana at Lafayette"},{"orgOrder":0,"company":"LCMC Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LCMC Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LCMC Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LCMC Health \/ Undisclosed"},{"orgOrder":0,"company":"Abramson Cancer Center at Penn Medicine","sponsor":"Johns Hopkins University | Translational Breast Cancer Research Consortium | Pfizer Inc | Breast Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Abramson Cancer Center at Penn Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abramson Cancer Center at Penn Medicine \/ Johns Hopkins University | Translational Breast Cancer Research Consortium | Pfizer Inc | Breast Cancer Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Abramson Cancer Center at Penn Medicine \/ Johns Hopkins University | Translational Breast Cancer Research Consortium | Pfizer Inc | Breast Cancer Research Foundation"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah | Utah Department of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ University of Utah | Utah Department of Health","highestDevelopmentStatusID":"10","companyTruncated":"Intermountain Health \/ University of Utah | Utah Department of Health"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ University of Utah","highestDevelopmentStatusID":"10","companyTruncated":"Intermountain Health \/ University of Utah"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Center for Outcomes Research and Education | Earle A. Chiles Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Center for Outcomes Research and Education | Earle A. Chiles Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Providence Health & Services \/ Center for Outcomes Research and Education | Earle A. Chiles Research Institute"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ National Institutes of Health"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"SUNY Downstate Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ SUNY Downstate Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ SUNY Downstate Medical Center"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Progenabiome","sponsor":"DSCS CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenabiome \/ DSCS CRO","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ DSCS CRO"},{"orgOrder":0,"company":"Progenabiome","sponsor":"DSCS CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenabiome \/ DSCS CRO","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ DSCS CRO"},{"orgOrder":0,"company":"United Health Group","sponsor":"ProHealth Care Associates | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Health Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Health Group \/ ProHealth Care Associates | University of Pennsylvania","highestDevelopmentStatusID":"8","companyTruncated":"United Health Group \/ ProHealth Care Associates | University of Pennsylvania"},{"orgOrder":0,"company":"Progenabiome","sponsor":"Big Corona","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenabiome \/ Big Corona","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ Big Corona"},{"orgOrder":0,"company":"Universidade do Vale do Sapucai","sponsor":"Pfizer Inc | Apsen Farmaceutica | Dermadia | Methodos Laboratory | Biofarma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Undisclosed","graph2":"Phase III","graph3":"Universidade do Vale do Sapucai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidade do Vale do Sapucai \/ Pfizer Inc | Apsen Farmaceutica | Dermadia | Methodos Laboratory | Biofarma","highestDevelopmentStatusID":"10","companyTruncated":"Universidade do Vale do Sapucai \/ Pfizer Inc | Apsen Farmaceutica | Dermadia | Methodos Laboratory | Biofarma"},{"orgOrder":0,"company":"Hospital do Coracao","sponsor":"Hospital Israelita Albert Einstein | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network | EMS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital do Coracao","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital do Coracao \/ Hospital Israelita Albert Einstein | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network | EMS","highestDevelopmentStatusID":"10","companyTruncated":"Hospital do Coracao \/ Hospital Israelita Albert Einstein | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network | EMS"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"EMS | Hospital do Coracao | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ EMS | Hospital do Coracao | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Israelita Albert Einstein \/ EMS | Hospital do Coracao | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network"},{"orgOrder":0,"company":"Salomeh Keyhani MD","sponsor":"San Francisco VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Salomeh Keyhani MD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Salomeh Keyhani MD \/ San Francisco VA Health Care System","highestDevelopmentStatusID":"10","companyTruncated":"Salomeh Keyhani MD \/ San Francisco VA Health Care System"},{"orgOrder":0,"company":"Yunfeng Cheng","sponsor":"Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Undisclosed","graph3":"Yunfeng Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","highestDevelopmentStatusID":"1","companyTruncated":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr."},{"orgOrder":0,"company":"Yunfeng Cheng","sponsor":"Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Undisclosed","graph3":"Yunfeng Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","highestDevelopmentStatusID":"1","companyTruncated":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr."},{"orgOrder":0,"company":"Yunfeng Cheng","sponsor":"Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Undisclosed","graph3":"Yunfeng Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","highestDevelopmentStatusID":"1","companyTruncated":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr."},{"orgOrder":0,"company":"Dr. Michael Hill","sponsor":"Alberta Health services | University of Alberta | University of Calgary | Calgary Health Trust | Alberta Innovates Health Solutions | Government of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Michael Hill","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Michael Hill \/ Alberta Health services | University of Alberta | University of Calgary | Calgary Health Trust | Alberta Innovates Health Solutions | Government of Alberta","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Michael Hill \/ Alberta Health services | University of Alberta | University of Calgary | Calgary Health Trust | Alberta Innovates Health Solutions | Government of Alberta"},{"orgOrder":0,"company":"Latin American Cooperative Oncology Group","sponsor":"Oncocl\u00ednicas","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Latin American Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latin American Cooperative Oncology Group \/ Oncocl\u00ednicas","highestDevelopmentStatusID":"8","companyTruncated":"Latin American Cooperative Oncology Group \/ Oncocl\u00ednicas"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"University Hospitals Geneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospitals Geneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Geneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University Hospitals Geneva \/ Undisclosed"},{"orgOrder":0,"company":"University of Cologne","sponsor":"Apogenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Cologne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cologne \/ Apogenix","highestDevelopmentStatusID":"9","companyTruncated":"University of Cologne \/ Apogenix"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The AIDS Clinical Trials Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The AIDS Clinical Trials Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Rising Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Rising Pharmaceuticals Inc"},{"orgOrder":0,"company":"Columbia University Irving Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Columbia University Irving Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University Irving Medical Center \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Columbia University Irving Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Utah Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah Health \/ Undisclosed"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Pcori","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ Pcori","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clinical Research Institute \/ Pcori"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Codebase","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codebase","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codebase \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Codebase \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter And Eliza Hall Institute Of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research"},{"orgOrder":0,"company":"Progenabiome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenabiome \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ Undisclosed"},{"orgOrder":0,"company":"Royal Melbourne Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Royal Melbourne Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Melbourne Hospital \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Royal Melbourne Hospital \/ Undisclosed"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"World Health Organization \/ Undisclosed"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Fibroblast Cell","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"FibroGenesis \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Hydroxychloroquine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Coronavirus Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 03, 2020

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Erythematosus, Systemic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 12, 2012

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Yunfeng Cheng

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Yunfeng Cheng

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Study Phase : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 28, 2024

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Yunfeng Cheng

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Yunfeng Cheng

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Study Phase : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 28, 2024

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Yunfeng Cheng

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Yunfeng Cheng

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Study Phase : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 28, 2024

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 26, 2023

                          Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 13, 2023

                          Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          May 03, 2023

                          Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Erythematosus, Systemic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 05, 2023

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 21, 2022

                          Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank